Skip to main content
Sartorius Stedim Biotech logo

Sartorius Stedim Biotech — Investor Relations & Filings

Ticker · DIM ISIN · FR0013154002 LEI · 52990006IVXY7GCSSR39 PA Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2026-02-03 Earnings Release
Country FR France
Listing PA DIM

About Sartorius Stedim Biotech

https://www.sartorius.com/en

Sartorius Stedim Biotech is a leading international provider of equipment and services for the biopharmaceutical industry. The company offers integrated solutions that support the entire lifecycle of drug development and manufacturing, from research and development to quality assurance and commercial production. Its comprehensive portfolio includes technologies for filtration, fluid management, fermentation, cell culture, and purification. Key products encompass bioreactors, single-use systems, process filtration equipment, cell culture media, and data analytics software. Sartorius Stedim Biotech enables its customers to develop and manufacture biotech medications, including cell and gene therapies, more efficiently and safely, helping to accelerate the translation of scientific discoveries into patient care.

Recent filings

Filing Released Lang Actions
Sartorius Stedim Biotech réalise une croissance rentable importante en 2025 et maintient des perspectives positives
Earnings Release Classification · 1% confidence The document is a press release from Sartorius Stedim Biotech dated February 3, 2026, detailing preliminary, unaudited financial results for the fiscal year 2025. It includes key financial highlights (revenue, EBITDA, net income), regional performance, and outlook for 2026. It is not a full Annual Report (10-K) as it explicitly states the full report will be published later (February 16, 2026). It is a standard initial announcement of periodic financial results, which fits the definition of an Earnings Release (ER). FY 2025
2026-02-03 French
Sartorius Stedim Biotech achieves considerable profitable growth in 2025 and maintains positive outlook
Earnings Release Classification · 1% confidence The document is a press release titled 'Sartorius Stedim Biotech achieves considerable profitable growth in 2025 and maintains positive outlook'. It provides preliminary, unaudited financial results for the fiscal year 2025, including sales revenue, EBITDA, and net profit, along with guidance for 2026. It is an initial announcement of financial performance rather than the full audited annual report (which is scheduled for publication on February 16, 2026). Therefore, it is classified as an Earnings Release. FY 2025
2026-02-03 English
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Share Issue/Capital Change Classification · 1% confidence The document is a formal declaration of the total number of shares and voting rights for Sartorius Stedim Biotech S.A., citing Article L 233-8-II of the French Code of commerce. This type of disclosure is a standard regulatory requirement for listed companies to update the market on their capital structure and voting rights. It does not represent a dividend announcement, a share buyback, or a major shareholding notification, but rather a periodic regulatory disclosure of the issued capital composition.
2026-02-02 English
Sartorius Stedim Biotech SA: DECLARATION RELATIVE AU NOMBRE D’ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change Classification · 1% confidence The document is a formal declaration regarding the number of shares and voting rights of Sartorius Stedim Biotech S.A. It explicitly references Article L 233-8-II of the French Commercial Code and Article 223-6 of the AMF General Regulation, which are standard regulatory requirements for disclosing share capital and voting rights. This type of disclosure is a standard regulatory filing for transparency in share capital structure.
2026-02-02 French
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Share Issue/Capital Change Classification · 1% confidence The document is a formal declaration by Sartorius Stedim Biotech SA regarding the total number of shares and voting rights as of January 31, 2026, in compliance with Article L 233-8-II of the French Code of commerce. This type of regulatory disclosure regarding capital structure and voting rights does not fit into specific categories like 'Share Issue' (SHA) or 'Major Shareholding' (MRQ) as it is a periodic administrative update of the company's own capital structure. Therefore, it is classified as a Regulatory Filing (RNS).
2026-02-02 English
Sartorius Stedim Biotech SA: Bilan semestriel du contrat de liquidité de la société Sartorius Stedim Biotech
Transaction in Own Shares Classification · 1% confidence The document is a 'Bilan semestriel du contrat de liquidité' (Half-year liquidity contract report) for Sartorius Stedim Biotech. It details the number of shares, cash balance, and transaction volumes for a liquidity contract managed by Kepler Cheuvreux. This type of disclosure is a standard regulatory requirement for companies listed on Euronext to report on their share buyback/liquidity programs. Since it is a periodic report on the company's own share transactions, it falls under the 'Transaction in Own Shares' category.
2026-01-06 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.